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.5%. As for participants without diabetes, those with an HbA1c level of 5.4% were at the lowest risk of all-cause mortality. When HbA1c level was lower than 5.0%, the increased allcause mortality risk became statistically significant as compared with an HbA1c level of 5.4%. However, we did not observe a statistically significant elevated risk of all-cause mortality above an HbA1c level of 5.4%. Conclusions: A U-shaped and a reverse J-shaped association for all-cause mortality were found among participants with and without diabetes. The corresponding Optimal ranges for overall survival are predicted to be 5.6-7.4% and 5.0-6.5%, respectively.
Introduction
Glycated hemoglobin (HbA1c) represents average endogenous exposure to glucose for the prior 2 to 3 months. 1 This biomarker has received much attention for its established relationship to type 2 diabetes and various vascular diseases, and for the rising national and global prevalence of hyperglycemia and diabetes. 2, 3 In 2010, the American Diabetes Association (ADA) proposed the use of an HbA1c level of 6.5% or higher as a threshold for the diagnosis of diabetes. 4, 5 In fact, over the past few decades, researchers have been examining the associations of HbA1c with various health outcomes among individuals with and without diabetes. As a result, growing epidemiological evidence has linked higher HbA1c with adverse health outcomes, such as cardiovascular disease, blindness, kidney failure and cancer, all of which may lead to premature death. [6] [7] [8] [9] However, concerns have been expressed regarding the optimal HbA1c ranges because hypoglycemia also may be hazardous and outweigh any potential benefit of glycemic control. 10, 11 To date, a conclusive relationship has not been demonstrated between HbA1c
and survival among different populations, and the true patterns of association are still an open issue, with some studies reporting non-linear relationships, 12, 13 whereas others suggesting no such associations. [14] [15] [16] This discrepancy has been a major obstacle to safely optimizing glycemic control, highlighting the need for further research to elucidate the safe glycemic range for survival.
In the current study, we investigated the range of HbA1c levels associated with all-cause mortality risk in participants with and without diabetes based on a sample of U.S. adults aged ≥ 50 years from the Health and Retirement Study (HRS). We further studied HbA1c and mortality due to cardiovascular disease, cancer and other causes. 
Methods
Design, study setting, and participants Initiated in 1992, the HRS is a longitudinal survey of a nationally representative sample of non-institutionalized adults aged ≥ 50 years in the U.S. 17 Biomarker data were collected biennially on subsamples since 2006. For these analyses we used four waves of the HRS covering 2006-2012. Respondents who met the following criteria were included in the study population: 1) completed an interview and had available data for HbA1c; 2) were without a history of cancer; 3) were aged 50 years and older; and 4) had reported their history of diabetes (yes/no). In total, 15,869 participants were eligible for our study. Specifically, 5,407, 5,168, 2,723 and 2,571 participants were included from the waves in 2006, 2008, 2010 and 2012, respectively. Diabetes cases (n= 3,824) were defined as a self-reported history of diabetes (n= 3,256) or no history of diagnosed diabetes but had elevated HbA1c levels ≥ 6.50% (n= 568). This definition provides the closest approximation of cases that could be classified as diabetes in clinical practice. 2 We followed HRS participants from the date of the initial interview to the date of death, loss to follow up, or last HRS interview (in the 2014 wave), whichever came first.
Assessment of HbA1c
In the HRS, HbA1c was measured by dried blood spots (DBS). The HRS adjusted DBS values to levels consistent with National Health and Nutrition Examination Survey (NHANES), exploiting the fact that weighted NHANES and HRS samples are both population-based studies aiming to represent the non-institutional U.S. population, and the population distributions should be the same. Specifically, the HRS determined the value of both assays at each percentile; and then transformed the DBS assays into the NHANES scale with adjustment for between-lab differences. 18 It has been reported that the distribution of the DBS assays is similar to that in NHANES. 19 The HbA1c results based on DBS are highly correlated with the whole blood (r=0.956), and have low within-assay imprecision and between-assay imprecision (1.4% and 2.2%, respectively.
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Assessment of deaths
Causes and time of death were determined by matching study records to the National Death Index and by exit interviews with proxy respondents. In our study, the primary outcome was all-cause mortality; the secondary outcomes were mortality due to cardiovascular disease, cancer and other causes. If the causes of death were heart, circulatory and blood conditions, it was classified as cardiovascular mortality. Cancer mortality was determined if the cause of death was recorded as cancer. Other mortality was defined as any deaths due to neither cardiovascular disease nor cancer.
Covariates
Participants' socio-demographic information (age, education level, sex and race), lifestyle (alcohol drinking and smoking status), and health conditions (history of cancer, diabetes, hypertension, heart disease, lung disease, mental health, psychiatric problems and stroke) were obtained. Anthropometric variables and biological indicators (C-reactive protein and total cholesterol) were also used. Body mass index (BMI) was calculated as weight in 21 The HRS applied a measure termed 'total recall' to reflect cognitive function. Specifically, a total of 20 points are derived from a memory task in which participants were asked to recall a list of unrelated nouns in the immediate trial (10 points) and the delayed trial (10 points) separately.
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Statistical analysis
Non-normally distributed data were described by medians and interquartile ranges (IQR), and Mann-Whitney U tests were applied to test for differences. Normally distributed data were described by means and standard deviation (SD), and differences were tested using unpaired t tests. Categorical data were described by frequencies and percentages, and the differences were analyzed by chi square tests. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) with 95% confidential intervals (CIs) of all-cause and causespecific mortality.
We applied Cox models with penalised splines using non-parametric smoothers to examine the potential non-linear or irregular relationship of the hazard functions. 23, 24 Flexible spline terms for HbA1c in fully adjusted Cox models with penalised splines were used for the participants with or without diabetes, with the corresponding degrees of freedom as 4 according to the Akaike information criterion (AIC).
The Cox models were adjusted for potential confounders which may be associated with both HbA1c and mortality. Three models with different adjustments were used: the first model was adjusted for age, sex, and race (white/Caucasian, black/African American or other); the second model was further adjusted for other baseline characteristics and life-style, including BMI (continuous), education level [less than high school, general educational development (GED), high-school graduate, some college or college and above], smoking (never, ever or current) and drinking (no or does not drink, 1-4 days/week, 5-7 days/week); the third fully adjusted model was additionally adjusted for health conditions and biological indicators, including cognitive function scores (continuous), CES-D (continuous), hypertension (yes/no), heart disease (yes/no), stroke (yes/no), lung disease (yes/no), psychiatric problems (yes/no), C-reactive protein (continuous), and total cholesterol (continuous).
As for participants with diabetes, the increased all-cause mortality risk became statistically significant when HbA1c level was lower than 5.60% or higher than 7.37% as compared with an HbA1c level of 6.52% (nadir point) (as shown in Figure 1 ). We subsequently stratified those with diabetes into low (≤ 5.60%), medium (> 5.60 & < 7.37%) and high (≥ 7.37%) groups based on the observed U-shaped curve. Individuals in the low group were further divided into 2 subgroups [denoted very low (< 5.40%) and medium-low (5.40-5.60%)] using the median (5.40%) of the low group, while the subjects in the high group were also similarly divided into 2 subgroups [denoted very high (> 8.43%) and medium-high (7.37-8.43%)] using the median (8.43%) of the high group. As a result, those with diabetes were grouped into 5 categories: very low (< 5.40%), medium-low (5.40-ADVANCE ARTICLE: As for those without diabetes, our data showed that participants with an HbA1c < 5.02% had a higher all-cause mortality risk as compared with those with an HbA1c level of 5.38% (nadir point) (as shown in Figure 1 ). However, we did not observe a statistically significant elevated risk of all-cause mortality above an HbA1c level of 5.38%. Based on the reverse Jshaped curve, we first stratified those without diabetes into low (≤ 5.02%) and medium (> 5.02). The low group was further divided into two subgroups [denoted very low (< 4.88%) and low (4.88-5.02%)] based on the median (4.88%) of this category. The medium group was also divided into two subgroups [denoted medium-low (> 5.02% & < 5.38%) and mediumhigh (≥ 5.38%)] based on the nadir point (5.38%). We further stratified medium-high into two groups using the median (5.70%) of this category [denoted medium-high 1 (5.38-5.70%) and medium-high 2 (> 5.70%)]. Finally, those without diabetes were divided into 5 groups: very low (< 4.88%), low (4.88-5.02%), medium-low (> 5.02% & < 5.38%, reference group), medium-high 1 (5.38-5.70%) and medium-high 2 (> 5.70%).
Supplementary analyses were also conducted based on prior relevant publications and possible clinical significance. Accordingly, 5 groups were generated for participants with diabetes: < 6.00%, ≥ 6.00 & < 6.50%, ≥ 6.50 & < 7.50% (reference category, given the largest number of participants), ≥ 7.50 & < 8.50%, ≥ 8.50%. Separately, participants without diabetes were initially grouped into 4 categories mainly according to ADA recommendations 25 : < 5.00% (suspected hypoglycemia), ≥ 5.00 & < 5.7% (normoglycemia, reference category) and 5.70-6.49% (prediabetes). The prediabetes category was further divided into two subgroups as for a previous study 12 : ≥ 5.70 & < 6.00% and 6.00-6.49% (denoted by low and high risk for adverse outcomes). In sensitivity analyses, we repeated the analysis with exclusion of those with a history of stroke, heart disease and lung disease for all-cause mortality in order to test the robustness of the results. Individuals who died within the first 2 years of follow-up were also excluded. In addition, given the possibility of haemoglobinopathies, those with low HbA1c levels (< 4.50%) were also excluded for sensitivity analyses.
We conducted subgroup analyses of the associations between HbA1c and mortality by age group (< 65 years, ≥ 65 years), sex (men/women), race (white/Caucasian, black/African American, or other), and BMI (< 25, ≥ 25). We also explored the possible interactions between HbA1c and aforementioned characteristics with respect to all-cause mortality. Statistical significance of the interactions was assessed by adding a product term into the model.
We used STATA, version 13 (StataCorp., College Station, Texax) to conduct the primary analyses. Cox models with penalised splines were conducted using R version 3.4.2 (R foundation for Statistical Computing). All P-values were 2-tailed, and the significance level was set at an alpha level of 0.05.
Results
Baseline characteristics
ADVANCE ARTICLE: The median level of HbA1c was 6.70% and 5.49% for participants with and without diabetes, respectively. Baseline characteristics for each of these two populations are shown in Table 1 . Compared with participants without diabetes, those with diabetes were more likely to be older, male, black/African American, to have higher BMI, less education, lower cognitive scores, higher levels of C-reactive protein, and lower levels of total cholesterol. They were also more likely to be ever smokers, reporting no drinking, and with a history of stroke, heart disease, lung disease, psych problems, and hypertension.
HbA1c and all-cause mortality among participants with diabetes
As shown in the fully adjusted model, a U-shaped association for HbA1c with all-cause mortality was observed in participants with diabetes (P for non-linearity = 0.03; Figure 1 ). The minimum mortality was associated with HbA1c values of 6.52%. Compared with HbA1c level of 6.52%, HbA1c levels ranging from 5.60% to 7.37% did not significantly predict a higher mortality risk. To compare the ranges of HbA1c with mortality risk, we analyzed Cox proportional hazards models with the medium range of (5.60-7.37%) HbA1c as the reference group, after which a greater mortality risk was found in the very high group (> 8.43%), with a fully adjusted HR of 1.40 (95% CI: 1.09, 1.80). We also found an elevated risk of mortality (HR: 1.66; 95% CI: 1.19, 2.33) in the very low group (< 5.40%) ( Table 2) . We have observed similar trends using the clinically defined categories (Supplemental Table1).
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HbA1c and all-cause mortality among participants without diabetes A reverse J-shaped association for HbA1c with all-cause mortality was observed in participants without diabetes (Figure 1 ). The minimum mortality was associated with an HbA1c level of 5.38% (P for non-linearity = 0.04) (Figure 1) . Specifically, compared with HbA1c level of 5.38%, HbA1c levels ranging from 5.02% to 6.49% were not significantly associated with a higher mortality risk. Compared with the reference range of HbA1c (Medium-low, > 5.02 & < 5.38%), the predefined low group (HR: 1.30; 95% CI: 1.02, 1.65) and very low group (HR: 1.60; 95% CI: 1.21, 2.07) were associated with higher mortality risks ( Table 2 ). In addition, our results yielded similar associations of HbA1c levels with allcause mortality across clinically defined categories (Supplemental Table 1 ). 26 Specifically, participants in the suspected hypoglycemia group (< 5.00%) had a higher risk of all-cause mortality (HR=1.35; 95% CI: 1.12, 1.63), compared with the normoglycemic group (≥ 5.00 & < 5.7%).
HbA1c and cause-specific mortality among participants with diabetes ADVANCE ARTICLE:
The
A U-shaped association between HbA1c and other mortality was observed in participants with diabetes, with the lowest risk of death other than cardiovascular and cancer associated with an HbA1c level of 6.59% (P for non-linearity = 0.02) (Figure 2) . A similar but not statistically significant U-shaped pattern was also observed with respect to cancer and cardiovascular related mortality (Figure 3 ). This lack of statistical significance may be due to the limited sample size as reflected by the wide confidence intervals.
HbA1c and cause-specific mortality among participants without diabetes
The patterns of associations of HbA1c with cancer and other mortality among those without diabetes appeared to be reverse J-shaped (Figure 3) , with a clear upturn in the risk of mortality when HbA1c levels were lower than 4.89% and 5.11%, respectively. Notably, there was a non-significant increased risk of cardiovascular mortality below an HbA1c level of 5.80% among participants without diabetes. Results from penalised splines derived cut-offs and clinically defined categories yielded qualitatively similar results (Supplemental Table 2 , Supplemental Table 3 ).
26
Subgroup and sensitivity analyses
Overall, we observed similar results in all subgroups (age, sex, race, and BMI), and no evidence of significant interactions (all interaction term P values > 0.1). The results were broadly consistent after excluding participants with a history of stroke, heart disease or lung disease at baseline for all-cause mortality among participants with diabetes (Supplemental Table 4 ). 26 Exclusion of participants who were with low HbA1c levels (< 4.50%) or who died within the first 2 years after the baseline survey did not materially change the results (Supplemental Table 4 ).
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Discussion
The present cohort study was conducted in non-institutionalized American adults without a history of cancer and aged ≥ 50 years. After adjusting for potential demographic, lifestyle, and biological confounding factors, we observed a U-shaped association between HbA1c and all-cause mortality among participants with diabetes and an asymmetric reverse J-shaped association among those without diabetes. We also observed a U-shaped association between HbA1c and other mortality in participants with diabetes. There were also trends towards Ushaped associations when restricting our data to cardiovascular and cancer mortality among this population, although lack of statistical significance. The reverse J-shaped relationships in participants without diabetes were generally consistent in cancer and other mortality. However, our results suggested that the low HbA1c-mortality seem not to apply to the cardiovascular death among this non-diabetic population. In recent years, 'safe ranges' of HbA1c have been debated considering the fact that not only high but also low levels of HbA1c may predict adverse outcomes. Most observational studies investigating the association between HbA1c and mortality have categorized individuals into 'clinically relevant groups', [13] [14] [15] [27] [28] [29] although these cut-offs are somewhat arbitrary as the increase in mortality is not always continuous and does not start abruptly at a certain HbA1c level. Therefore, most of these observational studies have failed to accurately elucidate the precise ranges associated with low mortality risk. In our study, levels of HbA1c ADVANCE ARTICLE: Our findings are in general agreement with those of a large retrospective study of 27,965 diabetic patients from the general population (aged ≥ 50 years) in the U.K; the relationship between HbA1c and mortality was also generally U-shaped, with the best survival at an HbA1c level of about 7.50% during 22 years of follow-up. 30 In this study, the adjusted HR of all-cause mortality in the lowest HbA1c decile was 1.52 (95% CI: 1.32, 1.76), and in the highest HbA1c decile was 1.79 (95% CI: 1.56, 2.06). Similarly, in the post hoc analyses of the ACCORD trial, 31 which included 10,251 diabetic participants, the lowest risk of mortality in the control arm over 3.4 (median) years of follow-up was associated with HbA1c in the range of 7.00-8.00%. Low HbA1c levels have been associated with increased all-cause mortality among participants without diabetes in several studies. 12, 27, 32 For example, our findings are consistent with results from the German National Health Interview and Examination Survey 1998 (GNHIES98), in which low levels of HbA1c were linked to a high risk of all-cause mortality. 12 However, this study did not evaluate different causes of death, thereby preventing further interpretation. In the current study, we identified reverse J-shaped associations of HbA1c with cancer-related and other mortality; however, this association was not found for cardiovascular mortality. Overall, these results suggest that cancer and other mortality but not cardiovascular mortality may have contributed to all-cause mortality among participants without diabetes. It is also of note that our findings showed no increased risk of any types of mortality related to 'prediabetic' (5.70-6.40%) levels of HbA1c as proposed by the American Diabetes Association. However, a few studies have reported that prediabetes status may predict a risk of mortality. 32, 33 For example, in the Atherosclerosis Risk in Communities (ARIC) study, Aggarwal et al. reported a higher risk of all-cause mortality for prediabetes, relative to a reference group with HbA1c levels between 5.00 to 5.70%. 34 These inconclusive results may be explained in part by the clinical heterogeneity of the included population and by confounding factors associated with both low HbA1c and increased mortality. Another possible explanation may be differences in reference groups. Mechanisms underlying the mortality risks of high and low HbA1c may be quite different. For instance, individuals with diabetes and high HbA1c may be unaware of their disease status or may adhere poorly to medical advice and self-management, leading to elevated risk of diabetes related complications that are associated with a poor prognosis. 35, 36 As for individuals without diabetes, low HbA1c may be a marker of poor health status such as malnutrition, unfavorable profiles of red blood cell related factors, iron storage, and liver function or an early stage of chronic disease, 32, 34, 37 all of which may be related to unfavorable clinical processes and result in increased risk of morbidity and mortality. [38] [39] [40] ADVANCE ARTICLE:
On the other hand, the idea that low HbA1c levels are associated with mortality among participants with diabetes can at first seem counterintuitive. Many clinicians are now concerned about the detrimental effect of intensive therapy for individuals with diabetes as the ADA and the Endocrine Society suggest that preventing hypoglycemia in individuals with diabetes may be more important than tight glycemic control. 41 Our analyses also revealed that the rise in mortality rate was steeper and higher at the low end of the HbA1c distribution than at its high end among those with diabetes, further supporting this view. However, the cause of increased mortality for diabetic participants with low HbA1c remains unclear. It has been suggested that hypoglycemia, weight gain or drug interactions caused by different medications may contribute to excess mortality . 31, 42 Our findings revealed a nadir of all-cause mortality at HbA1c level of 6.52%, which is very close to the diagnostic criteria for diabetes proposed by the ADA (> 6.50%). 4 Notably, this cut-off point of HbA1c of 6.50% was based on the links between HbA1c and microvascular disease, especially retinopathy, 43 and was established under the presumption of a significant linear increased risk of diabetes related complications above this level of HbA1c. In fact, given that mortality is a more adverse health event than micro-vascular disease, a reevaluation of the current cut-off for diabetes of 6.50% may be warranted taking into account mortality.
The present study has several strengths. To our knowledge, this is the first study that performed Cox models with penalised splines to examine potential non-linear associations between HbA1c and mortality. Our study would contribute to the literature by further elucidating the optimal ranges of HbA1c for mortality among people with and without diabetes. Second, the current study was conducted using a nationally, representative sample of US adults; the use of the National Death Index ensured complete information on death. We were also able to report on cause-specific mortality risks. Although the sample sizes were relatively low to provide stable estimates related to some causes of deaths, these data could help power future studies. Further evidence is needed to corroborate our findings in a larger sample.
Some limitations regarding the present study were as follows. First, HbA1c measurements may be affected by various clinical conditions such as anemia, chronic renal failure and liver disease, 12 thus the present study should be interpreted with caution because the excess mortality observed in the low end of HbA1c distribution may be a reflection of poor health not fully captured even after extensive adjustment for comorbidities. A further limitation was that we used a single measurement of HbA1c at baseline, thus we are not able to examine the link between HbA1c variability (a marker of glycaemic control) and mortality. Moreover, we relied on self-report and HbA1c levels to define diabetes and non-diabetes; however, substantial population of those with HbA1c levels < 6.5% may be diabetic, prediabetic, or, with postprandial hyperglycemia, if their glycemic levels were evaluated precisely by oral glucose tolerance test (OGTT). Thus some misclassifications may have occurred. Second, we have no data on treatment of diabetes and we cannot exclude gestational diabetes and type 1 diabetes because of the lack of this information. In addition, as this study was observational, we also cannot exclude the presence of residual confounding ADVANCE ARTICLE: 
Conclusions
In summary, our findings suggested a U-shaped and a reverse J-shaped association for allcause mortality among participants with and without diabetes. Optimal ranges for overall survival are predicted by this study to be 5.60-7.37% and 5.02-6.49% for participants with and without diabetes, respectively. from Cox models with penalised splines. Multivariate analyses were adjusted for age, sex, race, BMI, education level, smoking, drinking, cognitive function scores, Center for Epidemiologic Studies -Depression scales scores, hypertension, heart disease, stroke, lung disease, psychiatric problems, C-reactive protein and total cholesterol. The levels of HbA1c associated with the lowest risk of all-cause mortality were used as references (6.52% for participants with diabetes; 5.38% for participants without diabetes). The bar chart indicates the distribution of HbA1c levels among participants with and without diabetes. 
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